Loading
Angiogenesis and VEGF in Cancer · Journal article
npj Precision Oncology · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic translational study identifying a LAMC2-positive partial EMT subtype in HNSCC that drives vasculogenic mimicry and resistance to anti-angiogenic therapy via TGF-β signaling. The work proposes a synergistic blockade strategy (TGF-β + anlotinib) but provides only pre-clinical and descriptive clinical evidence; it raises a testable hypothesis rather than demonstrating clinical benefit.
Mechanistic translational study integrating single-cell RNA sequencing, spatial transcriptomics, clinical cohort analysis, and experimental models. Head and neck squamous cell carcinoma patients from clinical cohorts; experimental HNSCC models. Intervention: Functional characterization of LAMC2; TGF-β blockade combined with anlotinib in experimental models. Compared with: LAMC2-low or other malignant subtypes; single-agent anlotinib or TGF-β blockade alone.
LAMC2+ pEMT subtype enriched at invasive front and associated with poor prognosis LAMC2-high subtype exhibits resistance to anlotinib-based neoadjuvant therapy TGF-β blockade synergizes with anlotinib to suppress tumor growth in functional assays
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The findings suggest LAMC2 and TGF-β signaling as potential biomarkers and therapeutic targets in HNSCC, but the proposed combination strategy requires prospective clinical validation before influencing treatment decisions.
Mechanistic study using transcriptomics and experimental models to propose a resistance pathway; lacks clinical trial evidence or outcome validation of the proposed therapeutic strategy.
As stated by the source record.
The findings suggest LAMC2 and TGF-β signaling as potential biomarkers and therapeutic targets in HNSCC, but the proposed combination strategy requires prospective clinical validation before influencing treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy with limited therapeutic options. Here we combine single-cell RNA sequencing, spatial transcriptomics, clinical cohorts, and experimental models to dissect malignant epithelial heterogeneity and its impact on disease progression and treatment response. We identify a malignant subtype characterized by partial epithelial–mesenchymal transition (pEMT), enriched at the invasive front and associated with poor prognosis. This pEMT subtype exhibits pronounced vasculogenic mimicry (VM) potential and resistance to anlotinib-based neoadjuvant therapy, driven by high expression of the extracellular matrix component LAMC2. Functional assays demonstrate that LAMC2 promotes proliferation, VM formation, and resistance to anti-angiogenic therapy. Mechanistically, TGF-β signaling enhances LAMC2-driven VM, while blockade of TGF-β synergizes with anlotinib to suppress tumor growth. In addition, LAMC2–CD44 interactions shape an immunosuppressive tumor microenvironment enriched in M2 macrophages, cancer-associated fibroblasts, and regulatory T cells. Together, these findings define a LAMC2 + pEMT subtype that mediates therapeutic resistance through the TGF-β–pEMT/LAMC2–VM axis, highlighting a potential strategy to overcome resistance and reprogram the HNSCC microenvironment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.